/
JUNS
$0.21-$0.07 (-25.00%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$13.5M
48M shares
52-week range
$0.17 – $3.33
1% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
43.44%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-5.28
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1.1M | $638.0K | $233.3K | $0 | $0 | $21.8K |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $4.2K |
| Gross profit | $0 | $1.1M | $638.0K | $233.3K | $0 | $0 | $17.6K |
| Gross margin | — | 100.0% | 100.0% | 100.0% | — | — | 80.6% |
| R&D | $685.7K | $1.6M | $1.4M | $942.8K | $954.8K | $492.7K | $2.1M |
| Operating income | −$2.2M | −$1.9M | −$3.9M | −$3.4M | −$3.9M | −$3.1M | −$8.9M |
| EBITDA | −$2.7M | −$1.6M | −$4.1M | −$4.2M | −$4.6M | −$2.2M | −$8.6M |
| Net income | −$3.0M | −$1.7M | −$4.4M | −$5.0M | −$4.8M | −$2.4M | −$8.6M |
| Net margin | — | -146.9% | -686.4% | -2125.2% | — | — | -39662.8% |
| EPS (diluted) | -0.35 | -0.19 | -0.44 | -0.15 | -0.14 | -0.08 | -0.25 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $12M | $0.06 | $0.06–$0.06 | 1 |
| 2027 | $7M | $-0.26 | $-0.26–$-0.26 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Jupiter Neurosciences, Inc. Common Stock
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
www.jupiterneurosciences.com- Employees
- 5
- IPO / List date
- Dec 3, 2024
- HQ
- JUPITER, FL
Held by traders on TradeandTell
No one on the platform currently holds JUNS.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in JUNS as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded JUNS yet.
